RESEARCH GUIDES
CJC-1295 DAC vs No DAC: Material Identity
CJC-1295, CJC 1295 no DAC and CJC + Ipamorelin are not complete descriptions of the same item. When comparing research and catalog documents, establish the exact material instead of relying on the shared part of its name.
Editorial team: JEWJITSU PEPTIDES · Reviewed · Report a correction
What distinguishes the CJC-1295 studied in research?
The CJC-1295 development paper describes a GHRH analogue with a reactive group enabling albumin binding. That feature is part of the studied structure, not simply an extra word in a product name. The paper includes laboratory and animal models; it should not be presented as proof of a human outcome.
Why keep DAC and No DAC separate?
Our catalog lists CJC1295 DAC and CJC1295 No DAC as distinct items with their own strengths and packs. Do not transfer a certificate or research finding between them merely because both names include CJC. If a document says only CJC-1295, clarify the tested material.
For scientific identification, compare the chemical description, sequence or identifier where available, alongside the method and batch. A sales shorthand alone does not establish identity.
An Ipamorelin blend is another item
The + in CJC-1295 + Ipamorelin denotes a blend. Read each component's labeled strength separately from the number of vials per pack. A single-material certificate cannot describe the entire mixture. Do not infer the CJC component's DAC status from an abbreviated blend name; check explicit documentation.
Reading a study without substituting another material
A 2006 clinical publication investigated long-acting CJC-1295 in healthy adults in short placebo-controlled studies. The tested material, population and follow-up define the scope of its findings. The study title is not evidence for every No DAC item, blend or different batch.